Free tool
Cell therapy stocks
We cover 9 companies grouped under the Cell therapy theme. The median market value in the group is $94.15M. Across the group, the median move over the past trading day is −2.91%. Price change over the past year runs from −49.4% to +61.4% across the middle 80 percent of the group, with a median of −24.1%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
9 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| LEGN | Legend Biotech Corporation | $4.02B | Mid cap | −40.44% | Nov 11, 2026 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.66B | Mid cap | +233.88% | Nov 5, 2026 |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +4.47% | Aug 27, 2026 |
| VCEL | Vericel Corporation | $2.17B | Mid cap | +18.25% | Nov 5, 2026 |
| ATRA | Atara Biotherapeutics, Inc. | $94.15M | Micro cap | −24.05% | Nov 12, 2026 |
| ACET | Adicet Bio, Inc. | $83.79M | Micro cap | −26.01% | Nov 11, 2026 |
| INKT | MiNK Therapeutics, Inc. | $60.16M | Micro cap | −26.22% | Nov 12, 2026 |
| TVGN | Tevogen Inc. | $43.63M | Micro cap | −85.43% | Nov 13, 2026 |
| LGVN | Longeveron Inc. | $21.68M | Micro cap | −14.44% | Nov 4, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.